Mar 18, 2013

Personalized Cancer Medicine project started. First samples being sequenced


We have started the sequencing of the first samples for the National Personalized Cancer Medicine project lead by the Norwegian Cancer Genomics Consortium. Approximately 200 samples from human melanoma patients will be exome sequenced using Agilent SureSelect Human All Exome V5 target enrichment technology.

We have started the sequencing of the first samples for the National Personalized Cancer Medicine project lead by the Norwegian Cancer Genomics Consortium. Approximately 200 samples from human melanoma patients will be exome sequenced using Agilent SureSelect Human All Exome V5 target enrichment technology.

 
 
 
 
 
 


News

Jan 18, 2018

Due to a resent hacker attack to the OUS IT system, we currently are unable to receive or send emails to the rr-research domain. Until further notice please use this email to contact us “genomics.cf.oslo@gmail.com”

Feb 24, 2016

The HiSeq 4000 build upon the existing HiSeq 2500 platform using the new HiSeq X patterned flow cell technology, providing unparalleled speed and performance. The dual-flow cell HiSeq 4000 System delivers the highest throughput and lowest price per sample across multiple applications. The new sequencer will provide users will faster turnaround time (run time is 3 days compared to 6-11 days in HiSeq 2500) and higher quality, more data per run and longer reads (150 bp paired-end).


Contact Information:

genomics.cf.oslo@gmail.com

Visiting address:
Genomics Core Facility (Room 3-F8-04)
Department of Core facilities
Institute for Cancer Research
New OCCI-building 
 
Norwegian Radium Hospital 
Ullernchaussen 66, Lamell 3, 2B 
NO-0379 Oslo, NORWAY

+47 - 9183 2772 Laboratory
+47 - 9183 3425 Office

Daily Leader Core Facility
Susanne Lorenz, PhD

Head of Core Facility
Leonardo A. Meza-Zepeda, Dr. philos.

................................................................

................................................................